Related Experiment Videos
ST2 and adrenomedullin in heart failure
1Division of Cardiology, Massachusetts General Hospital, Boston, MA 02114, USA. rkakkar@partners.org
Heart Failure Clinics
|July 28, 2009
Summary
Soluble ST2 and adrenomedullin levels in the blood can help predict outcomes for patients with heart failure. These biomarkers indicate biomechanical strain and risk for death in symptomatic heart failure.
Area of Science:
- Cardiology
- Biomarkers
- Heart Failure Research
Background:
- Interleukin-33 (IL-33) binds to the ST2 receptor, mediating antihypertrophic and antifibrotic effects in the heart.
- Soluble ST2 (sST2) in serum is a biomarker for ventricular biomechanical strain.
- Adrenomedullin is a vasoactive peptide counteracting heart failure pathophysiology.
Purpose of the Study:
- To evaluate the prognostic value of serum soluble ST2 (sST2) levels in patients with symptomatic heart failure.
- To assess the utility of serum adrenomedullin levels in identifying patients with advanced heart failure at high risk for mortality.
Main Methods:
- Measurement of serum levels of soluble ST2 (sST2).
- Measurement of serum levels of adrenomedullin.
- Correlation of biomarker levels with clinical outcomes and risk stratification in heart failure patients.
Main Results:
- Serum sST2 levels serve as a biomarker for ventricular biomechanical strain.
- Serum sST2 levels provide prognostic information in symptomatic heart failure.
- Serum adrenomedullin levels can identify patients with advanced heart failure at increased risk for heart failure-related death.
Conclusions:
- Serum sST2 is a valuable prognostic biomarker in symptomatic heart failure.
- Serum adrenomedullin is a useful biomarker for risk stratification in advanced heart failure.
- These biomarkers aid in identifying high-risk patients for targeted interventions.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...